JP2000504326A5 - - Google Patents

Download PDF

Info

Publication number: JP2000504326A5
Authority: JP; Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP1997526911A

Other languages

English (en)

Other versions

JP2000504326A (ja

Filing date

1997-01-23

Publication date

2005-06-16

1996-01-23 Priority claimed from US08/590,288 external-priority patent/US5741492A/en

1997-01-23 Application filed filed Critical

2000-04-11 Publication of JP2000504326A publication Critical patent/JP2000504326A/ja

2005-06-16 Publication of JP2000504326A5 publication Critical patent/JP2000504326A5/ja

Status Pending legal-status Critical Current

Description

JP9526911A 1996-01-23 1997-01-23 Ｈｉｖのｐｏｌｙｅｎｖワクチンとしての組換えワクシニアベクターの混合物 Pending JP2000504326A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/590,288 US5741492A (en)	1996-01-23	1996-01-23	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US08/590,288		1996-01-23
PCT/US1997/000669 WO1997027311A1 (en)	1996-01-23	1997-01-23	Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007186200A Division JP2007259870A (ja)	1996-01-23	2007-07-17	Ｄｎａワクチン及び組換えウイルスベクターとして作用し得る二機能性プラスミド

Publications (2)

Publication Number	Publication Date
JP2000504326A JP2000504326A (ja)	2000-04-11
JP2000504326A5 true JP2000504326A5 (ja)	2005-06-16

Family

ID=24361647

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP9526911A Pending JP2000504326A (ja)	1996-01-23	1997-01-23	Ｈｉｖのｐｏｌｙｅｎｖワクチンとしての組換えワクシニアベクターの混合物
JP2007186200A Pending JP2007259870A (ja)	1996-01-23	2007-07-17	Ｄｎａワクチン及び組換えウイルスベクターとして作用し得る二機能性プラスミド

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2007186200A Pending JP2007259870A (ja)	1996-01-23	2007-07-17	Ｄｎａワクチン及び組換えウイルスベクターとして作用し得る二機能性プラスミド

Country Status (29)

Country	Link
US (3)	US5741492A (ja)
EP (2)	EP0876498B1 (ja)
JP (2)	JP2000504326A (ja)
KR (1)	KR100571479B1 (ja)
CN (1)	CN1229501C (ja)
AP (1)	AP1200A (ja)
AT (1)	ATE278790T1 (ja)
AU (1)	AU709174B2 (ja)
BG (1)	BG64711B1 (ja)
BR (1)	BR9707611A (ja)
CA (1)	CA2243570C (ja)
CZ (1)	CZ296575B6 (ja)
DE (1)	DE69731075T2 (ja)
DK (1)	DK0876498T3 (ja)
EA (1)	EA002390B1 (ja)
ES (1)	ES2230596T3 (ja)
GE (1)	GEP20032902B (ja)
HK (1)	HK1016218A1 (ja)
HU (2)	HU224344B1 (ja)
IL (2)	IL156919A0 (ja)
NO (1)	NO322261B1 (ja)
NZ (1)	NZ331024A (ja)
OA (1)	OA10814A (ja)
PL (1)	PL188641B1 (ja)
PT (1)	PT876498E (ja)
RO (1)	RO120268B1 (ja)
TR (1)	TR199801418T2 (ja)
UA (1)	UA73712C2 (ja)
WO (1)	WO1997027311A1 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7488485B2 (en) *	2003-09-16	2009-02-10	University Of Kansas Medical Center	DNA vaccine compositions and methods of use
GB9711957D0 (en) *	1997-06-09	1997-08-06	Isis Innovation	Methods and reagents for vaccination
US20030138454A1 (en) *	1997-06-09	2003-07-24	Oxxon Pharmaccines, Ltd.	Vaccination method
US6919318B1 (en) *	1998-04-22	2005-07-19	Chiron Corporation	Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) *	1998-05-22	1999-12-02	University Of Massachusetts Medical Center	Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) *	1998-10-30	2003-05-13	University Of Southern California	Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en)	1998-11-05	2004-07-06	The Trustees Of The University Of Pennsylvania	Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP2002538770A (ja) *	1998-11-10	2002-11-19	ユニバーシティオブノースカロライナアットチャペルヒル	ウイルスベクターとその製造及び投与の方法
US6689879B2 (en)	1998-12-31	2004-02-10	Chiron Corporation	Modified HIV Env polypeptides
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en)	1998-12-31	2013-05-07	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) *	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1144014B1 (en) *	1999-01-28	2005-07-27	Stichting Biomedical Primate Research Center	Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors
DE19907485B4 (de) *	1999-02-12	2008-01-17	Strathmann Ag & Co.	Virus-Vakzine
US6420545B1 (en) *	1999-05-24	2002-07-16	The Trustees Of The University Of Pennsylvania	CD4-independent HIV envelope proteins as vaccines and therapeutics
WO2001037878A2 (en) *	1999-11-29	2001-05-31	Orchid Biosciences, Inc.	Methods of identifying optimal drug combinations and compositions thereof
US8623379B2 (en) *	2000-03-02	2014-01-07	Emory University	Compositions and methods for generating an immune response
CA2401974C (en)	2000-03-02	2013-07-02	Emory University	Dna expression vectors and methods of use
US20040105871A1 (en) *	2000-03-02	2004-06-03	Robinson Harriet L.	Compositions and methods for generating an immune response
AU2001283094A1 (en) *	2000-08-07	2002-02-18	Sloan-Kettering Institute For Cancer Research	Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
ATE499948T1 (de) *	2001-01-12	2011-03-15	Novartis Vaccines & Diagnostic	Nukleinsäure mukosale immunisierung
JP4554887B2 (ja) *	2001-03-08	2010-09-29	アメリカ合衆国	改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
JP5033303B2 (ja)	2001-07-05	2012-09-26	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
CA2452119C (en) *	2001-07-05	2013-10-15	Chiron Corporation	Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
GB0118532D0 (en) *	2001-07-30	2001-09-19	Isis Innovation	Materials and methods relating to improved vaccination strategies
WO2003020876A2 (en) *	2001-08-31	2003-03-13	Chiron Corporation	Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20030228327A1 (en) *	2001-11-05	2003-12-11	Lasher Alfred W.	DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20070269456A1 (en) *	2001-11-05	2007-11-22	Lasher Alfred W	DNA-based plasmid formulations and vaccines and prophylactics containing the same
JP2005517639A (ja)	2001-11-30	2005-06-16	イシスイノベーションリミテッド	ワクチン
US6923958B2 (en) *	2002-03-02	2005-08-02	The Scripps Research Institute	DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US7094410B2 (en) *	2002-03-02	2006-08-22	The Scripps Research Institute	DNA vaccine against proliferating endothelial cells and methods of use thereof
US20040106566A1 (en) *	2002-05-17	2004-06-03	Shi-Lung Lin	RNA-splicing and processing-directed gene silencing and the relative applications thereof
ATE494907T1 (de) *	2002-07-18	2011-01-15	Univ Washington	Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
AU2003298912B2 (en) *	2002-12-03	2011-06-02	Advanced Bioscience Laboratories, Inc.	Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US7658927B2 (en) *	2003-05-12	2010-02-09	University Of Florida Research Foundation, Inc.	Materials and methods for immunizing against FIV infection
BRPI0410422A (pt)	2003-05-12	2006-05-30	Univ Florida	materiais e processos para para imunização contra infecção por fiv
US8076060B2 (en) *	2003-08-04	2011-12-13	Emil William Chynn	Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
JP2007505130A (ja) *	2003-09-09	2007-03-08	バイレクシスコーポレイション	ヒトにおいてｈｉｖに対する免疫応答を生成するための、レンチウイルスベクターベースのアプローチ
EP1675613B1 (en)	2003-09-15	2012-05-23	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Hiv vaccines based on env of multiple clades of hiv
EP1667631A4 (en) *	2003-09-15	2010-04-14	Novartis Vaccines & Diagnostic	COMBINED APPROACHES TO PRODUCE IMMUNE RESPONSES
US20050175627A1 (en) *	2003-09-24	2005-08-11	Oxxon Therapeutics Ltd.	HIV pharmaccines
US7622125B2 (en)	2004-05-05	2009-11-24	Novartis Vaccines And Diagnostics, Inc.	Polycistronic HIV vector constructs
AU2005249450A1 (en)	2004-05-27	2005-12-15	Centocor, Inc.	Cynomolgus prostate specific antigen
WO2006101503A2 (en) *	2004-06-15	2006-09-28	Centocor, Inc.	Method for screening agents against human prostate disease
ATE527281T1 (de) *	2004-07-16	2011-10-15	Us Gov Health & Human Serv	Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
US20080085261A1 (en) *	2004-10-19	2008-04-10	Haynes Barton F	Vaccine Adjuvant
EP2266602A3 (en)	2004-11-01	2011-08-10	Novartis Vaccines and Diagnostics, Inc.	Combination approaches for generating immune responses
AU2005316476A1 (en) *	2004-12-15	2006-06-22	University Of Florida Research Foundation, Inc.	Chimeric vectors
WO2008048984A2 (en) *	2006-10-18	2008-04-24	St. Jude Children's Research Hospital	Methods and compositions for preparing a universal influenza vaccine
US8889641B2 (en)	2009-02-11	2014-11-18	The University Of North Carolina At Chapel Hill	Modified virus vectors and methods of making and using the same
WO2012070974A1 (ru) *	2010-11-22	2012-05-31	Farber Boris Slavinovich	Вакцины с повышенной иммуногенностью и способы их получения
ES2714692T3 (es) *	2011-01-31	2019-05-29	Tau Bio Logic Corp	Tratamiento de tauopatías
US9839684B2 (en)	2011-04-06	2017-12-12	Biovaxim Limited	Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
CA2855826A1 (en)	2011-11-14	2013-05-23	Novartis Ag	Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof
WO2013126622A1 (en)	2012-02-24	2013-08-29	President And Fellows Of Harvard College	Methods for displaying polypeptides and uses thereof
EA038974B1 (ru) *	2015-12-15	2021-11-17	Янссен Вэксинс Энд Превеншн Б.В.	Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
WO2020201828A1 (en)	2019-04-05	2020-10-08	Tauc3 Biologics Limited	Anti-tauc3 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5198214A (en) *	1983-08-31	1993-03-30	Stolle Research & Development Corporation	Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
GR862412B (en) *	1985-09-25	1987-01-23	Oncogen	Vaccines and immuinoassays for acquired immune deficiency syndrome
EP0243029A1 (en) *	1986-04-08	1987-10-28	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Recombinant vaccinia virus expressing human retrovirus gene
US5169763A (en) *	1986-04-08	1992-12-08	Transgene S.A., Institut Pasteur	Viral vector coding glycoprotein of HIV-1
US5081226A (en) *	1986-12-30	1992-01-14	The United States Of America As Represented By The Department Of Health And Human Services	Synthetic peptides sharing sequence homology with the HIV envelope protein
WO1990012880A1 (en) *	1989-04-18	1990-11-01	Applied Biotechnology, Inc.	Generation of hybrid genes and proteins by virus-mediated recombination
EP1156102A1 (en) *	1991-06-14	2001-11-21	Virogenetics Corporation	Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) *	1992-03-23	1997-07-01	University Of Massachusetts Medical Center	Immunization by inoculation of DNA transcription unit
DE69536091D1 (de) *	1994-01-27	2010-09-09	Univ Massachusetts Medical	Immunisierung durch Impfung von DNS Transkriptionseinheit
FR2728794B1 (fr) *	1994-12-30	1997-03-21	Rhone Merieux	Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro

1996
- 1996-01-23 US US08/590,288 patent/US5741492A/en not_active Expired - Lifetime
1997
- 1997-01-23 EA EA199800638A patent/EA002390B1/ru not_active IP Right Cessation
- 1997-01-23 DE DE69731075T patent/DE69731075T2/de not_active Expired - Lifetime
- 1997-01-23 TR TR1998/01418T patent/TR199801418T2/xx unknown
- 1997-01-23 IL IL15691997A patent/IL156919A0/xx unknown
- 1997-01-23 HU HU9900389A patent/HU224344B1/hu not_active IP Right Cessation
- 1997-01-23 DK DK97903823T patent/DK0876498T3/da active
- 1997-01-23 NZ NZ331024A patent/NZ331024A/en not_active IP Right Cessation
- 1997-01-23 HU HU0402182A patent/HU0402182D0/hu unknown
- 1997-01-23 WO PCT/US1997/000669 patent/WO1997027311A1/en active IP Right Grant
- 1997-01-23 PT PT97903823T patent/PT876498E/pt unknown
- 1997-01-23 KR KR1019980705646A patent/KR100571479B1/ko not_active IP Right Cessation
- 1997-01-23 PL PL97328193A patent/PL188641B1/pl unknown
- 1997-01-23 EP EP97903823A patent/EP0876498B1/en not_active Expired - Lifetime
- 1997-01-23 CZ CZ0229398A patent/CZ296575B6/cs not_active IP Right Cessation
- 1997-01-23 AU AU18299/97A patent/AU709174B2/en not_active Ceased
- 1997-01-23 CN CNB971932344A patent/CN1229501C/zh not_active Expired - Fee Related
- 1997-01-23 IL IL125497A patent/IL125497A/en not_active IP Right Cessation
- 1997-01-23 UA UA98084523A patent/UA73712C2/uk unknown
- 1997-01-23 ES ES97903823T patent/ES2230596T3/es not_active Expired - Lifetime
- 1997-01-23 EP EP03077363A patent/EP1378516A1/en not_active Ceased
- 1997-01-23 CA CA002243570A patent/CA2243570C/en not_active Expired - Fee Related
- 1997-01-23 GE GEAP19974458A patent/GEP20032902B/en unknown
- 1997-01-23 RO RO98-01218A patent/RO120268B1/ro unknown
- 1997-01-23 BR BR9707611A patent/BR9707611A/pt not_active Application Discontinuation
- 1997-01-23 AP APAP/P/1998/001325A patent/AP1200A/en active
- 1997-01-23 US US08/788,815 patent/US5846546A/en not_active Expired - Lifetime
- 1997-01-23 JP JP9526911A patent/JP2000504326A/ja active Pending
- 1997-01-23 AT AT97903823T patent/ATE278790T1/de active
1998
- 1998-07-22 NO NO19983377A patent/NO322261B1/no not_active IP Right Cessation
- 1998-07-22 OA OA9800118A patent/OA10814A/en unknown
- 1998-08-21 BG BG102712A patent/BG64711B1/bg unknown
- 1998-09-21 US US09/157,963 patent/US6086891A/en not_active Expired - Lifetime
1999
- 1999-03-24 HK HK99101230A patent/HK1016218A1/xx not_active IP Right Cessation
2007
- 2007-07-17 JP JP2007186200A patent/JP2007259870A/ja active Pending

Publication	Publication Date	Title
JP2000502280A5 (ja)	2005-06-16
JP2000501771A5 (ja)	2004-08-19
JP2001505109A5 (ja)	2005-07-14
JP2000501599A5 (ja)	2005-05-12
JP2000509281A5 (ja)	2005-01-13
JP2000500076A5 (ja)	2005-07-14
JP2001507395A5 (ja)	2005-02-10
JP2000500055A5 (ja)	2005-04-07
JP2000500026A5 (ja)	2004-10-21
JP2000502472A5 (ja)	2005-06-16
JP2000501825A5 (ja)	2005-04-07
JP2000504326A5 (ja)	2005-06-16
JP2000502485A5 (ja)	2005-04-07
JP2000501774A5 (ja)	2005-04-07
JP2000502425A5 (ja)	2005-02-10
JP2000502570A5 (ja)	2004-11-18
JP2000502568A5 (ja)	2004-11-11
JP2000501876A5 (ja)	2005-04-07
JP2000501744A5 (ja)	2004-11-11
JP2000502316A5 (ja)	2005-04-07
JP2000502714A5 (ja)	2004-11-11
JP2001512348A5 (ja)	2005-01-13
JP2000500318A5 (ja)	2005-04-07
JP2000501569A5 (ja)	2005-05-12
JP2000502479A5 (ja)	2005-06-16